

CITATION REPORT

List of articles citing

Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect

DOI: 10.1124/jpet.110.170191

Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 1023-30.

Source: <https://exaly.com/paper-pdf/49021699/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
88	Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. <i>Cellular and Molecular Life Sciences</i> , 2004 , 61, 1157-66	10.3	19
87	Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. <i>Oxidative Medicine and Cellular Longevity</i> , 2010 , 3, 428-33	6.7	49
86	Phosphodiesterase-5 Inhibitors in Protection Against Doxorubicin-Induced Cardiomyopathy. 2011 , 243-255		
85	Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. <i>Drug Metabolism Reviews</i> , 2011 , 43, 540-57	7	49
84	Phosphodiesterases and cardiac cGMP: evolving roles and controversies. <i>Trends in Pharmacological Sciences</i> , 2011 , 32, 360-5	13.2	73
83	Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect. <i>Yearbook of Cardiology</i> , 2011 , 2011, 350-355		
82	Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 2512-24	5.6	20
81	Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis. <i>Cellular Signalling</i> , 2011 , 23, 1094-9	4.9	52
80	Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). <i>Expert Opinion on Therapeutic Patents</i> , 2011 , 21, 1631-41	6.8	19
79	Mechanisms and management of doxorubicin cardiotoxicity. <i>Herz</i> , 2011 , 36, 296-305	2.6	131
78	Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine. <i>Circulation Research</i> , 2011 , 108, 1040-1041	15.7	2
77	Heart failure: a PKGarious balancing act. <i>Circulation</i> , 2012 , 126, 797-9	16.7	3
76	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5590-606	3.3	14
75	Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/- mice. <i>Anti-Cancer Drugs</i> , 2012 , 23, 584-9	2.4	6
74	Phosphodiesterases and cyclic GMP regulation in heart muscle. <i>Physiology</i> , 2012 , 27, 248-58	9.8	38
73	Cardiac uses of phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 9-15	15.1	65
72	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1921-7	15.1	58

71	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <i>Current Heart Failure Reports</i> , 2012 , 9, 192-9	2.8	26
70	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. <i>PLoS ONE</i> , 2012 , 7, e45243	3.7	65
69	Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. <i>Stem Cells</i> , 2012 , 30, 326-35	5.8	52
68	Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. <i>Basic Research in Cardiology</i> , 2012 , 107, 249	11.8	24
67	Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. <i>Andrologia</i> , 2012 , 44 Suppl 1, 370-5	2.4	9
66	Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms. <i>Fundamental and Clinical Pharmacology</i> , 2013 , 27, 271-8	3.1	10
65	Complications of chemotherapy, a basic science update. <i>Presse Medicale</i> , 2013 , 42, e352-61	2.2	24
64	Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. <i>Journal of Cardiology</i> , 2013 , 62, 110-6	3	25
63	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. <i>Free Radical Biology and Medicine</i> , 2013 , 60, 80-8	7.8	62
62	Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line. <i>Chemical and Pharmaceutical Bulletin</i> , 2013 , 61, 405-10	1.9	7
61	Sildenafil exposure and hemodynamic effect after Fontan surgery. <i>Pediatric Critical Care Medicine</i> , 2014 , 15, 28-34	3	33
60	Effects of tadalafil on hemorrhagic cystitis and testicular dysfunction induced by cyclophosphamide in rats. <i>Urologia Internationalis</i> , 2014 , 93, 55-62	1.9	7
59	Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. <i>Biomedicine and Pharmacotherapy</i> , 2014 , 68, 101-10	7.5	60
58	Diabetic Cardiomyopathy. 2014 ,		2
57	Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1 β signaling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014 , 306, H1558-68	5.2	61
56	Priming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafil. <i>Future Cardiology</i> , 2015 , 11, 177-89	1.3	5
55	Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. <i>European Journal of Pharmacology</i> , 2015 , 765, 574-81	5.3	10
54	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. <i>Pharmacology & Therapeutics</i> , 2015 , 147, 12-21	13.9	144

53	Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin. <i>PLoS ONE</i> , 2016 , 11, e0154994	3.7	12
52	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. <i>Oncotarget</i> , 2016 , 7, 4399-413	3.3	29
51	Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G 1 β Oxidation. <i>Journal of Biological Chemistry</i> , 2016 , 291, 17427-36	5.4	34
50	Preventing antineoplastic drug-related cardiomyopathy: old and new therapeutic strategies. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S64-75	1.9	18
49	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. <i>Cardiovascular Research</i> , 2016 , 111, 154-62	9.9	32
48	Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 356, 284-92	4.7	13
47	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. <i>Sexual Medicine Reviews</i> , 2017 , 5, 170-198	9.8	11
46	Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. <i>Canadian Journal of Physiology and Pharmacology</i> , 2017 , 95, 295-304	2.4	7
45	Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 3277-3287	5.6	26
44	Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. <i>Tumor Biology</i> , 2017 , 39, 1010428317695016	2.9	6
43	Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases. <i>Annual Review of Pharmacology and Toxicology</i> , 2017 , 57, 455-479	17.9	61
42	Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice. <i>Antioxidants and Redox Signaling</i> , 2017 , 26, 153-164	8.4	11
41	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017 , 8, 99179-99202	3.3	28
40	Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. <i>Journal of Cardiovascular Medicine</i> , 2018 , 19, 315-323	1.9	19
39	Effects of phosphodiesterase type 5 inhibitors in epinephrine-induced arrhythmia in rats: Involvement of lactate dehydrogenase and creatine kinase downregulation and adiponectin expression. <i>Human and Experimental Toxicology</i> , 2018 , 37, 256-264	3.4	6
38	Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. <i>British Journal of Pharmacology</i> , 2018 , 175, 223-231	8.6	21
37	The environmental pollutant BDE-209 regulates NO/cGMP signaling through activation of NMDA receptors in neurons. <i>Environmental Science and Pollution Research</i> , 2018 , 25, 3397-3407	5.1	5
36	Antiproliferative activity of the combination of doxorubicin/quercetin on MCF7 breast cancer cell line: A combined study using colorimetric assay and synchrotron infrared microspectroscopy. <i>Infrared Physics and Technology</i> , 2018 , 95, 141-147	2.7	8

35	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. <i>Cardio-Oncology</i> , 2018 , 4,	2.8	9
34	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. <i>Frontiers in Physiology</i> , 2018 , 9, 167	4.6	74
33	Phosphodiesterase inhibitors say NO to Alzheimer's disease. <i>Food and Chemical Toxicology</i> , 2019 , 134, 110822	4.7	33
32	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019 , 30, 2110-2153	8.4	73
31	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020 , 177, 5467-5488	8.6	34
30	Myocardial Phosphodiesterases and Their Role in cGMP Regulation. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 483-493	3.1	15
29	Targets of cGMP/cGKI in Cardiac Myocytes. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 494-507	3.1	4
28	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1874, 188383	11.2	9
27	Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 401-417	3.9	7
26	GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. <i>Archives of Toxicology</i> , 2020 , 94, 2113-2130	5.8	9
25	Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats. <i>Reproductive Toxicology</i> , 2020 , 96, 165-174	3.4	13
24	Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity. <i>Antioxidants and Redox Signaling</i> , 2021 , 34, 572-588	8.4	4
23	Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. <i>Molecules</i> , 2021 , 26,	4.8	4
22	Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. <i>PLoS ONE</i> , 2013 , 8, e77713	3.7	73
21	The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities. <i>PLoS ONE</i> , 2016 , 11, e0153694	3.7	4
20	Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction ROS/eNOS/NO Pathway. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1531	5.6	32
19	A Review on the Potential Benefits of Phosphodiesterase Inhibitors in Various Models of Toxicities in Animals. <i>Asian Journal of Animal and Veterinary Advances</i> , 2012 , 7, 210-224	0.1	3
18	Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond. <i>Annals of Translational Medicine</i> , 2016 , 4, 65	3.2	4

17	Phosphodiesterase-5 Inhibitors in Cardioprotection. 2013 , 439-458		
16	PDE-5 Inhibitors in Protection of Diabetic Heart. 2014 , 323-338		
15	The Phosphodiesterase-5 Inhibitors and Prostate Cancer [What We Rely Know About It?]. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019 ,	0.3	
14	Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. <i>Molecular and Cellular Pharmacology</i> , 2010 , 2, 173-178		17
13	Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. <i>Experimental and Clinical Cardiology</i> , 2011 , 16, e30-5		39
12	Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 812578	5.4	2
11	Sildenafil for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: A Phase I/II Randomized Clinical Trial, SILDAT-TAHA6 Trial.. <i>Cardiology Research and Practice</i> , 2022 , 2022, 5681510	1.9	
10	Tadalafil in Increasing Doses: The Influence on Coronary Blood Flow and Oxidative Stress in Isolated Rat Hearts.. <i>Pharmacology</i> , 2021 , 1-10	2.3	1
9	Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 847012	5.4	0
8	DataSheet_1.pdf. 2020 ,		
7	TRPC6 N338S is a gain-of-function mutant identified in patient with doxorubicin-induced cardiotoxicity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022 , 1868, 166505	6.9	0
6	Potential cardiotoxicity induced by Euodiae Fructus: In vivo and in vitro experiments and untargeted metabolomics research. 13,		0
5	The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.		0
4	Cardiotoxicity linked to anticancer agents and cardioprotective strategy.		0
3	Phosphodiesterase 5a Signalling in Skeletal Muscle Pathophysiology. 2023 , 24, 703		1
2	Nitric Oxide-cGMP-PKG Signaling in the Cardioprotective Effects of Phosphodiesterase 5 Inhibitors. 2023 , 111-126		0
1	Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil. 2023 , 324, R589-R600		1